Search clinical trials for: Rivaroxaban placebo

Total 54220 results

Centre of Postgraduate Medical Education

Unknown

Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.

Blood Loss | Hip Osteoarthritis

Poland
Insel Gruppe AG, University Hospital Bern

Completed

Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial (ELAN)

Ischaemic Stroke

Belgium, Ireland, Israel, Germany, India, United Kingdom, Austria, Switzerland, Finland, Norway, Italy, Portugal, Slovakia, Japan, Greece
University of Padova

Completed

Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy (ERIKA)

Venous Thromboembolism | Haemorrhage

Italy
Pfizer

Completed

A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France (SIFNOS)

Atrial Fibrillation

France
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon (ReLoaDeD)

Atrial Fibrillation

Germany
Boehringer Ingelheim
Health ResearchTx, LLC (HRTX); inVentiv Health Clinical (iVH); United States...

Completed

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty (XAMOS)

Venous Thromboembolism

Switzerland, China, Slovakia, France, Germany, Hungary, Korea, Republic of, Singapore, South Africa, Spain, Sweden, Philippines, Australia, Austria, Colombia, Czech Republic, Estonia, Hong Kong, Italy, Latvia, Lebanon, Lithuania, Macedonia... and more
Bristol-Myers Squibb

Completed

Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients

Atrial Fibrillation
Bristol-Myers Squibb

Completed

Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

Atrial Fibrillation
Susan Smyth
Janssen Scientific Affairs, LLC

Terminated

XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis (XENITH)

Venous Thrombosis | Pulmonary Embolism
Bayer
Janssen Research & Development, LLC

Completed

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction (CALLIPER)

Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions

Pharmacokinetics

Germany
Bayer

Completed

ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial (ODiXaHip)

Thromboembolism | Prevention

Belgium, Denmark, Austria, Germany, Netherlands, Poland, Sweden, Israel, France, Norway, United Kingdom
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement. (RECORD 3)

Venous Thromboembolism | Prevention

Belgium, Italy, Poland, Spain, China, France, Denmark, Netherlands, Austria, Germany, Mexico, South Africa, Sweden, Colombia, Israel, Canada, Norway, Peru, Czech Republic
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Switching Study From Warfarin to Rivaroxaban

Venous Thrombosis

Germany
Henan Institute of Cardiovascular Epidemiology

Completed

Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty

Acute Coronary Syndrome

China
Bayer
Janssen Research & Development, LLC

Completed

Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA LEA)

Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)

Turkey, Russian Federation, Korea, Republic of, Mexico, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Egypt, Kazakhstan, Algeria, Lebanon, Saudi Arabia, Ukraine, Jordan, Kenya, Kuwait, Morocco, Qatar, United Arab Emirates
David Anderson
Canadian Institutes of Health Research (CIHR)

Completed

Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (EPCAT II)

Venous Thromboembolism

Canada
First Affiliated Hospital Xi'an Jiaotong University

Completed

Anticoagulation Therapy After Splenectomy in Cirrhosis Patient (ATASICP)

Liver Cirrhosis | Thrombosis | Portal Hypertension | Anticoagulant-induced Bleeding

China
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists

Atrial Fibrillation

Germany
Bayer
Janssen Research & Development, LLC

Completed

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

Atrial Fibrillation

Germany
Shenyang Northern Hospital

Not yet recruiting

Rivaroxaban or Aspirin in Patients With CHD & GD Undergoing PCI

Rivaroxaban
Fundació Institut de Recerca de l'Hospital de la...
Daiichi Sankyo

Recruiting

Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD) (MACACOD)

Atrial Fibrillation | Recurrent Venous Thromboembolism

Spain
University of Florida
Janssen Scientific Affairs, LLC

Completed

Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies

Coronary Artery Disease | Peripheral Arterial Disease | Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners (PRACTISE)

Venous Thromboembolism (VTE)

Sweden
Janssen Research & Development, LLC
Bayer

Completed

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

Healthy | Renal Insufficiency

United States
Xijing Hospital

Recruiting

Low-dose NOAC Versus GDMT After LAAO (RECORD-III)

Atrial Fibrillation

China
National Cancer Institute (NCI)

Completed

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Glioma | Glioblastoma Multiforme | Giant Cell Glioblastoma | Oligodendrogliomas | Astrocytoma, Grades II, III and IV

United States
Asan Medical Center
Bayer

Recruiting

Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation (SPIRIT)

Coronary Artery Disease | Peripheral Arterial Disease | Carotid Stenosis | Atherosclerosis of Artery

Korea, Republic of
University College, London

Active, not recruiting

OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial (OPTIMAS)

Atrial Fibrillation | Stroke, Acute

United Kingdom
University of California, San Francisco
Patient-Centered Outcomes Research Institute; Kaiser Permanente

Completed

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study (ALTERNATIVE)

Venous Thromboembolism | Anticoagulants and Bleeding Disorders

United States
Radboud University Medical Center

Active, not recruiting

Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease (DUALCAD)

Coronary Artery Disease

Netherlands
Duke University
Patient-Centered Outcomes Research Institute

Terminated

Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism (COVET)

Venous Thromboembolism

United States
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

Healthy

United States
Regeneron Pharmaceuticals

Completed

Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants

Healthy Volunteer

United Kingdom
National Taiwan University Hospital

Recruiting

Evaluataion of NOAC Levels in Acute Stroke

Ischemic Stroke | Anticoagulant Adverse Reaction

Taiwan
University of Birmingham
University of Oxford; University Hospital Birmingham NHS Foundation Trust; London... and other collaborators

Recruiting

Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation (DaRe2THINK)

Atrial Fibrillation

United Kingdom
RWTH Aachen University
Bayer

Completed

Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification

Atrial Fibrillation or Pulmonary Embolism | Need of Long Term Oral Anticoagulation Therapy (OAT) | Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location

Germany
Bayer

Completed

Accessibility to New Drugs Versus SOC in Sweden

Anticoagulation

Sweden
Beijing Suncadia Pharmaceuticals Co., Ltd

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
Radboud University Medical Center
Amgen

Completed

Rivaroxaban Sotorasib Interaction Study (ROSIE)

Drug Drug Interaction Study

Netherlands
Pharmtechnology LLC
ClinPharmInvest, LLC

Not yet recruiting

Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions

Bioequivalence

Russian Federation
Rajaie Cardiovascular Medical and Research Center
Tehran Heart Center

Completed

Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI (REWARF-STEMI)

ST Segment Elevation Myocardial Infarction | Left Ventricular Thrombus

Iran, Islamic Republic of
Radboud University Medical Center

Completed

DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease (DUAL-PAD)

Peripheral Artery Disease

Netherlands
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Venous Thrombosis

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, United States, New Zealand, Poland, India, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Brazil, Denmark, Germany, Norw... and more
Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)

Myocardial Infarction | Ischemic Stroke | Atrial Fibrillation | All-cause Mortality | Systemic Embolization | Major Bleed

Canada
Bayer
Janssen Research & Development, LLC

Terminated

A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients. (PROTECT-AF)

Non-valvular Atrial Fibrillation

Norway
Ahmed AbdelMoneim Hassan Ali
Beni-Suef University

Unknown

Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin

Surgery--Complications | Thromboses, Deep Vein
Bayer

Completed

Anticoagulation Preference by AF Patients Study (PRiSMA-AF)

Atrial Fibrillation

Switzerland
Gines Escolar
Ministry of Health, Spain

Unknown

Reversal of the Antithrombotic Action of New Oral Anticoagulants (REVANT)

Hemorrhage | Thrombosis | Anticoagulant-induced Bleeding | Anticoagulant Overdosage

Spain

Search clinical trials for: Rivaroxaban placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations